Research Centre

Clinical Research is expanding at Marsden Eye Specialists. Dr Jennifer Arnold and Dr Ashish Agar co-ordinates the research team of Ophthalmologists, Orthoptists and Registered Nurses. The department currently has 13 ongoing international and local clinical trials. The main focus of research is on new treatments for Age Related Macular Degeneration, Diabetic Macular Oedema, Retinal Vein Occlusions, Polypoidal Choroidal Vasculopathy and Glaucoma. Patients enrolled in these trials have access to new advanced treatments that are in the final stages of development prior to approval and release.

Please contact Clinical Trials Co-ordinator Trish Forsyth on or email [javascript protected email address] if you would like further information.

Research Team

  • Dr Jennifer Arnold – Principal Investigator (AMD, DME, BRVO, CRVO, PCV Trials)
  • Dr Ashish Agar – Principal Investigator (Glaucoma Trials)
  • Dr Gavin Stringfellow, Dr Kwon Kang, Dr Alan Luckie, Dr Derek Chan, Dr John Chang, Dr Terence Tan, Dr Helene Cass and Dr Carolyn Ross – Sub Investigators.
  • Mara Giribaldi, Ivy Chow, Amy Hawkins, Angela Chung, Caroline Chahine, Lara Collis, Hariette Ayson, Catherine Severino – VA, OCT, FA technicians
  • Trish Forsyth – Study Co-ordinator
  • Anh Nguyen – Clinical Trials Assistant
  • Julie Boland – Study Nurse

Current Recruitment Clinical Trials

Wet AMD

Allergan Inc. International - Allergan Australia Pty Ltd: SEQUOIA STUDY

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (Recruitment Open)

EPS Global Research Pty Ltd: OPH1004 study

A PHASE 3 RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS ADMINISTRATION OF FOVISTA TM (ANTI PDGF-B PEGYLATED APTAMER) ADMINISTERED IN COMBINATION WITH EITHER AVASTIN® OR EYLEA® COMPARED TO AVASTIN® OR EYLEA® MONOTHERAPY IN SUBJECTS WITH SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (Recruitment Open)

Dry AMD

Roche Products, Pty, Limited: Chroma Study

A PHASE III, MULTICENTER, RANDOMIZED,DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION GX29176 (Recruitment Open)

Roche Products Pty Limited: Proxima B Study

A MULTICENTER, PROSPECTIVE EPIDEMIOLOGIC STUDY OF THE Progression OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION (Recruitment Open)

Apellis Pharmaceuticals, Inc.: Filly Study

A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients with Geographic Atrophy (GA) – FILLY (Recruitment Open)

Glaucoma

Allergan Inc. International - Allergan Australia Pty Ltd: Atermis Study

The Efficacy and Safety of Bimatoprost SR in Patients with Open-angle Glaucoma or Ocular Hypertension.(Recruitment Open)

Current Clinical Trials

Alcon Research, Ltd.: Hawk Study

A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration (recruitment closed)

Novartis Pharmaceuticals:FLUID STUDY

A Phase IV, randomised, controlled single masked study investigating the efficacy and safety of ranibizumab "inject and extend" using an intensive retinal fluid retreatment regimen compared to a relaxed retinal fluid retreatment regimen in patients with wet age-related macular degeneration (AMD).(recruitment closed)

Novartis Pharmaceuticals:RIVAL STUDY

Development of new geographic atrophy in patients with neovascular (wet) age-related macular degeneration: a comparison of ranibizumab and aflibercept (recruitment closed)

Bayer Schering Pharmaceuticals: PLANET

A randomized, double-masked, sham-controlled phase 3b/4 study of the efficacy, safety, and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic therapy as indicated in subjects with polypoidal choroidal vasculopathy (PLANET)(recruitment closed)

EPS Global Research Pty Ltd: OPH1003 study

STUDY TITLE: A phase 3 Randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous ADMINISTRATION of FovistaTM (anti PDGF-b pegylated aptamer) administered in combination with Lucentis® COMPARED TO LUCENTIS® MONOTHERAPY in subjects with subfoveal neovascular age-related macular degeneration (recruitment closed)

Novartis Pharmaceuticals: CONTROL Study

An open-label, multi-centre, 12-month study to evaluate the comparative efficacy of Lucentis (ranibizumab) 0.5mg intravitreal injection in patients with diabetic macular oedema (DME) with well controlled and poorly controlled diabetes mellitus. (recruitment closed)

Novartis Pharmaceuticals: LUMINOUS Study

Study to observe the effectiveness and safety of LUCENTIS® through individualized patient treatment and associated outcomes. (recruitment closed)

Ellex R&D and Centre for Eye Research Australia (CERA):

Laser Intervention in Early Age-Related Macular Degeneration (LEAD) Study

A multi-centre, randomized trial into the safety and efficacy of nanosecond microsurgical laser intervention in early age-related macular degeneration. (recruitment closed)

Completed Clinical Trials

Australia by Clinical Network Services (CNS) Pty Ltd, Internationally Apellis Pharmaceuticals, Inc: ASAP II STUDY

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Patients with Neovascular Age-Related Macular Degeneration (AMD) –ASAP II

Alcon Research Ltd: Safety And Efficacy Of Nepafenac

C-12-071: Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery

Bayer Schering Pharmaceuticals:Efficacy and safety of VEGF Trap-Eye in DME with central involvement

A randomized, double-masked, active-controlled phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema

Novartis Pharmaceuticals: Central Retinal Vein Occlusion (CRVO) CRYSTAL Study

A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5mg ranibizumab intravitreal injections applied as monotherapy in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO)

Novartis Pharmaceuticals: Branch Retinal Vein Occlusion (BRVO) BRIGHTER Study

A 24-month, phase IIIb, open-label, randomized, active-controlled, 3 arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5 mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO).

Please contact Clinical Trials Co-ordinator Trish Forsyth on or email [javascript protected email address] if you would like further information.